150,119 Shares in Enovis Co. (NYSE:ENOV) Bought by Invenomic Capital Management LP

Invenomic Capital Management LP bought a new position in Enovis Co. (NYSE:ENOV) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 150,119 shares of the company’s stock, valued at approximately $6,587,000. Invenomic Capital Management LP owned about 0.26% of Enovis as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. UMB Bank n.a. raised its position in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company’s stock worth $677,000 after buying an additional 2,518 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Enovis in the fourth quarter worth about $437,000. Tributary Capital Management LLC lifted its position in shares of Enovis by 33.9% during the 4th quarter. Tributary Capital Management LLC now owns 566,089 shares of the company’s stock valued at $24,840,000 after buying an additional 143,258 shares in the last quarter. Finally, Park Avenue Securities LLC grew its stake in shares of Enovis by 12.5% during the 4th quarter. Park Avenue Securities LLC now owns 11,988 shares of the company’s stock valued at $526,000 after acquiring an additional 1,333 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Shares of NYSE:ENOV opened at $33.05 on Friday. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -15.09 and a beta of 1.79. The firm has a fifty day moving average price of $35.20 and a 200 day moving average price of $41.56. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $53.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. During the same quarter in the prior year, the firm earned $0.50 EPS. The business’s revenue was up 8.2% on a year-over-year basis. As a group, sell-side analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ENOV has been the topic of several recent analyst reports. JMP Securities decreased their price objective on shares of Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research report on Friday. Needham & Company LLC lowered their price objective on Enovis from $64.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.